

References

This is the reference list to the ACE Clinical Guidance "Gout – achieving the management goal".

1. Khanna D, Fitzgerald JD, Khanna PP, et al. 2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. *Arthritis Care Res.* 2012;64(10):1431-1446.
2. Richette P, Doherty M, Pascual E, et al. 2016 updated EULAR evidence-based recommendations for the management of gout. *Ann Rheum Dis.* 2017;76(1):29-42.
3. Rees F, Jenkins W, Doherty M. Patients with gout adhere to curative treatment if informed appropriately: proof-of-concept observational study. *Ann Rheum Dis.* 2013;72(6):826-830.
4. Bursill D, Taylor WJ, Terkeltaub R, et al. Gout, Hyperuricaemia and Crystal-Associated Disease Network (G-CAN) consensus statement regarding labels and definitions of disease states of gout. *Ann Rheum Dis.* 2019;78(11):1592-1600.
5. Fitzgerald JD, Dalbeth N, Mikuls T, et al. 2020 American College of Rheumatology guideline for the management of gout. *Arthritis Care Res.* 2020;72(6):744-760.
6. National Institute for Health and Care Excellence (NICE). Gout: diagnosis and management (NICE guideline NG219). 2022. Available from: <https://www.nice.org.uk/guidance/ng219> [Accessed 9 September 2023].
7. Malaysian Health Technology Assessment Section (MaHTAS). Management of Gout (Second Edition). 2021. Available from: <https://www.moh.gov.my/index.php/pages/view/3962> [Accessed 9 September 2023].
8. Becker MA, Schumacher HR, MacDonald PA, et al. Clinical efficacy and safety of successful longterm urate lowering with febuxostat or allopurinol in subjects with gout. *J Rheumatol.* 2009;36(6):1273-1282.
9. Schumacher HR Jr, Becker MA, Lloyd E, et al. Febuxostat in the treatment of gout: 5-yr findings of the FOCUS efficacy and safety study. *Rheumatology.* 2009;48(2):188-194.
10. Becker MA, Schumacher HR, Jr., Wortmann RL, et al. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. *N Engl J Med.* 2005;353(23):2450-2461.
11. Doherty M, Jenkins W, Richardson H, et al. Efficacy and cost-effectiveness of nurse-led care involving education and engagement of patients and a treat-to-target urate-lowering strategy versus usual care for gout: a randomised controlled trial. *Lancet.* 2018;392(10156):1403-1412.
12. National Institute for Health and Care Excellence (NICE). Gout: diagnosis and management (NICE guideline NG219) – Evidence review [G] urate-lowering therapies for the long-term management of gout. 2022. Available from: <https://www.nice.org.uk/guidance/ng219> [Accessed 9 September 2023].
13. Huang X, Du H, Gu J, et al. An allopurinol-controlled, multicenter, randomized, double-blind, parallel between-group, comparative study of febuxostat in chinese patients with gout and hyperuricemia. *Int J Rheum Dis.* 2014;17(6):679-686.
14. Schumacher Jr HR, Becker MA, Wortmann RL, et al. Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: A 28-week, phase III, randomized, double-blind, parallel-group trial. *Arthritis Care Res.* 2008;59(11):1540-1548.
15. White WB, Saag KG, Becker MA, et al. Cardiovascular safety of febuxostat or allopurinol in patients with gout. *N Engl J Med.* 2018;378(13):1200-1210.
16. Mackenzie IS, Ford I, Nuki G, et al. Long-term cardiovascular safety of febuxostat compared with allopurinol in patients with gout (FAST): a multicentre, prospective, randomised, open-label, non-inferiority trial - supplementary appendix. *Lancet.* 2020;396(10264).
17. Stamp LK, Barclay ML. How to prevent allopurinol hypersensitivity reactions? *Rheumatology.* 2018;57(Suppl 1):i35-i41.
18. Lee MH, Graham GG, Williams KM, et al. A benefit-risk assessment of benzbromarone in the treatment of gout. Was its withdrawal from the market in the best interest of patients? *Drug Saf.* 2008;31(8):643-665.
19. Wortmann RL, Macdonald PA, Hunt B, et al. Effect of prophylaxis on gout flares after the initiation of urate-lowering therapy: analysis of data from three phase III trials. *Clin Ther.* 2010;32(14):2386-2397.

20. Yamanaka H, Tamaki S, Ide Y, et al. Stepwise dose increase of febuxostat is comparable with colchicine prophylaxis for the prevention of gout flares during the initial phase of urate-lowering therapy: results from FORTUNE-1, a prospective, multicentre randomised study. *Ann Rheum Dis.* 2018;77(2):270-276.
21. Dong D, Tan-Koi WC, Teng GG, et al. Cost-effectiveness analysis of genotyping for HLA-B*5801 and an enhanced safety program in gout patients starting allopurinol in Singapore. *Pharmacogenomics.* 2015;16(16):1781-1793.
22. Lorenzo JPP, Sollano MHMZ, Salido EO, et al. 2021 Asia-Pacific League of Associations for Rheumatology clinical practice guideline for treatment of gout – supplementary file. *Int J Rheum Dis.* 2022;25(1):7-20.
23. European Medicines Agency. EPAR – summary of risk management plan for Adenuric (febuxostat). 2019. Available from: https://www.ema.europa.eu/en/documents/rmp-summary/adenueric-epar-risk-management-plan-summary_en.pdf [Accessed 9 September 2023].
24. Terkeltaub RA, Furst DE, Bennett K, et al. High versus low dosing of oral colchicine for early acute gout flare: Twenty-four-hour outcome of the first multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-comparison colchicine study. *Arthritis Rheum.* 2010;62(4):1060-1068.